Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from ...